138 related articles for article (PubMed ID: 17285451)
1. American Society of Hematology--48th Annual Meeting and Exposition. 9-12 December 2006, Orlando, FL, USA.
Walker K
IDrugs; 2007 Feb; 10(2):75-7. PubMed ID: 17285451
[No Abstract] [Full Text] [Related]
2. Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
Melo JV; Chuah C
Hematology Am Soc Hematol Educ Program; 2008; ():427-35. PubMed ID: 19074121
[TBL] [Abstract][Full Text] [Related]
3. A widening prospect: Imatinib and novel applications of targeted therapy.
Rowinsky EK
Semin Oncol; 2004 Apr; 31(2 Suppl 6):1-3. PubMed ID: 15175997
[No Abstract] [Full Text] [Related]
4. Imatinib: resisting the resistance.
Rothberg PG
Leuk Res; 2003 Nov; 27(11):977-8. PubMed ID: 12859989
[No Abstract] [Full Text] [Related]
5. STI571 (glivec-tm): a new paradigm for the development of innovative therapies in onco-hematology?
Gambacorti C
Tumori; 2001; 87(6):S10-2. PubMed ID: 11989608
[No Abstract] [Full Text] [Related]
6. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
7. American Society of Hematology--48th Annual Meeting and Exposition. Therapeutic approaches for hematological cancers. 9-12 December 2006 Orlando, FL, USA.
Tear S
IDrugs; 2007 Feb; 10(2):84-6. PubMed ID: 17285454
[No Abstract] [Full Text] [Related]
8. Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells.
Ju DS; Kim MJ; Bae JH; Song HS; Chung BS; Lee MK; Kang CD; Lee HS; Kim DW; Kim SH
Cancer Lett; 2007 Jul; 252(1):75-85. PubMed ID: 17223257
[TBL] [Abstract][Full Text] [Related]
9. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia.
Manley PW; Cowan-Jacob SW; Mestan J
Biochim Biophys Acta; 2005 Dec; 1754(1-2):3-13. PubMed ID: 16172030
[TBL] [Abstract][Full Text] [Related]
10. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
Okabe S; Tauchi T; Nakajima A; Sashida G; Gotoh A; Broxmeyer HE; Ohyashiki JH; Ohyashiki K
Stem Cells Dev; 2007 Jun; 16(3):503-14. PubMed ID: 17610380
[TBL] [Abstract][Full Text] [Related]
11. American Society of Hematology--48th Annual Meeting and Exposition. Treatments for leukemia and lymphoma. 9-12 December 2006 Orlando, FL, USA.
Talmadge JE
IDrugs; 2007 Feb; 10(2):87-9. PubMed ID: 17285455
[No Abstract] [Full Text] [Related]
12. [Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia].
Grzybowska-Izydorczyk O; Góra-Tybor J; Robak T
Postepy Hig Med Dosw (Online); 2006; 60():490-7. PubMed ID: 17013368
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.
Tipping AJ; Baluch S; Barnes DJ; Veach DR; Clarkson BM; Bornmann WG; Mahon FX; Goldman JM; Melo JV
Leukemia; 2004 Aug; 18(8):1352-6. PubMed ID: 15201856
[TBL] [Abstract][Full Text] [Related]
14. American Society of Hematology--48th Annual Meeting and Exposition. Updates on hematological therapies. 9-12 December 2006 Orlando, FL, USA.
Walker K
IDrugs; 2007 Feb; 10(2):78-80. PubMed ID: 17285452
[No Abstract] [Full Text] [Related]
15. [STI571: a summary of targeted therapy].
Czyz M; Jakubowska J
Postepy Hig Med Dosw (Online); 2006; 60():677-96. PubMed ID: 17245318
[TBL] [Abstract][Full Text] [Related]
16. Mutational analysis and overcoming imatinib resistance in chronic myeloid leukemia with novel tyrosine kinase inhibitors.
Mauro MJ
Curr Treat Options Oncol; 2007 Aug; 8(4):287-95. PubMed ID: 18157514
[No Abstract] [Full Text] [Related]
17. Treating imatinib-resistant leukemia: the next generation targeted therapies.
Burgess MR; Sawyers CL
ScientificWorldJournal; 2006 Aug; 6():918-30. PubMed ID: 16906325
[TBL] [Abstract][Full Text] [Related]
18. David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies.
Druker BJ
J Clin Oncol; 2003 Dec; 21(23 Suppl):239s-245s. PubMed ID: 14645403
[No Abstract] [Full Text] [Related]
19. [Tyrosine kinase inhibitors for the treatment of CML].
Heim D
Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
[TBL] [Abstract][Full Text] [Related]
20. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
